Less than one in 10 people that would benefit from obesity jabs like Wegovy can access them, states the World Health Organization as it releases its initial advice on the drugs.
Given in excess of 1,000,000,000 individuals worldwide now obese, it is advocating for more widespread and fairer access to these injectable treatments.
Per forecasts, over two billion could be living with obesity by 2030 unless action is taken.
"The new guidelines recognises that obesity is a long-term condition that can be managed with thorough and lifelong treatment," said the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and supply-chain constraints are significant barriers to broad access to the jabs that can aid individuals in losing substantial weight, notes the agency.
Weight-Loss Drug Shortage
Even in the current most optimistic outlook, the supply of these medications could only cover around 100 million people – under 10% of those who need them, according to the health organization.
The recommendation urges nations and manufacturers to expand access, through measures including licensing agreements.
Exclusive production rights on the active ingredient – the core component of the drug Wegovy – is scheduled to end in multiple countries in 2026.
The Way Weight-Loss Drugs Operate
GLP-1 drugs replicate a biological compound to reduce digestion speed, reduce hunger and enhance the sense of being full so users reduce food intake.
Individuals usually start to lose weight within a few weeks of starting on the weekly injections.
Research suggests people may put most of the weight back on a year later of discontinuing the treatment, as their usual hunger return.
Being carrying excess weight elevates your chance for experiencing health problems, including type 2 diabetes, cardiovascular issues, brain attack, and specific malignancies.
Obesity concerns individuals in countries worldwide and was associated with 3.7 million fatalities worldwide in 2024, as per the WHO.
